{"disease":{"id":"phase-1","name":"phase 1"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odm-108-part-iii","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part III","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not publicly disclosed","drug_class":"Unknown — investigational small molecule","quality_score":null,"revenue":null,"mechanism":"ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers."},{"drug_id":"odm-108-part-i","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part I","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not disclosed","drug_class":"Small molecule (investigational)","quality_score":null,"revenue":null,"mechanism":"ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated."},{"drug_id":"pf-07899895","indication_name":"Undisclosed indication (Phase 1 terminated)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07899895","generic_name":"pf-07899895","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not disclosed","drug_class":"Unknown","quality_score":null,"revenue":null,"mechanism":"Mechanism of action not disclosed; Phase 1 study terminated before pharmacological characterization."}],"offLabel":[],"totalMarketed":0,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT07288957","title":"A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT03983876","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Alvotech Swiss AG","has_results":false},{"nct_id":"NCT07362888","title":"First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Adcendo ApS","has_results":false},{"nct_id":"NCT07337941","title":"Menstrual Cycle Phase and Virtual Reality on Preoperative Anxiety","phase":"NA","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Zonguldak Bulent Ecevit University","has_results":false},{"nct_id":"NCT02689440","title":"Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07434609","title":"Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanolattix Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT00254423","title":"Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07218003","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":149,"lead_sponsor_name":"Rondo Therapeutics","has_results":false},{"nct_id":"NCT03744468","title":"Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00796068","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03817398","title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00390793","title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02506933","title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03589729","title":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04338867","title":"Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07252479","title":"Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Adlai Nortye Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT03263572","title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01424982","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02220985","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03654768","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06214858","title":"The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"JKT Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT03273192","title":"A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT02530034","title":"Hu8F4 in Treating Patients With Advanced Hematologic Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05007873","title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01445080","title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04327089","title":"Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":false},{"nct_id":"NCT01823198","title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02396134","title":"Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05226702","title":"Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University of Saskatchewan","has_results":false},{"nct_id":"NCT03630991","title":"Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01904136","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01746836","title":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07413367","title":"A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tonix Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06527300","title":"A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Zhejiang Wenda Pharma Technology LTD.","has_results":false},{"nct_id":"NCT07020533","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07500298","title":"Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03516279","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03883620","title":"Safety Study of Dengushield in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT06660420","title":"Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03488719","title":"A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Saniona","has_results":true},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07401875","title":"A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}